Linnaeus Therapeutics
PrivateLast Round
Grant
Feb 17, 2026
Total Funding Raised
$27.39M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Linnaeus Therapeutics operates in Healthcare & Life Sciences and is based in Haddonfield, New Jersey. Its latest recorded funding round was a Series B round in August 2025.
Linnaeus Therapeutics is a biotechnology company that develops and commercializes novel small molecule oncology therapeutics targeting G protein-coupled receptors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Linnaeus Therapeutics Comparables
Compare Linnaeus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EPICS Therapeutics | 78% | |
| HiberCell | 76% | |
| GPCR Therapeutics | 75% |
For institutional investors. Book with your work email.
Linnaeus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 17, 2026 | ||||
| Series B | Aug 22, 2025 | ||||
| Grant | Mar 26, 2025 | ||||
| VC Round | Nov 12, 2024 | ||||
| Early Funding | Jan 24, 2023 | ||||
Grant | Apr 6, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Linnaeus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| University of Pennsylvania Office of Investments | Series A |
| NIH RADx | Grant |
| Kairos Ventures | Series B, Series A |
| Kairos Ventures | Series B, Series A |
| ARPA-H | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 199% MoM, reaching 1.6K.
- Mar 10, 2026
Melanoma drug trial to begin, funded by $4.5M financing.
For institutional investors. Book with your work email.
Linnaeus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Linnaeus Therapeutics's valuation, stock price, and market status.
Is Linnaeus Therapeutics a public or private company?
Linnaeus Therapeutics is a private company.
What is the current stock price of Linnaeus Therapeutics?
Linnaeus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Linnaeus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Linnaeus Therapeutics worth (valuation)?
Valuation information for Linnaeus Therapeutics is not publicly available.
Can I buy Linnaeus Therapeutics stock?
Linnaeus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Linnaeus Therapeutics's last funding round?
Linnaeus Therapeutics's most recent funding round was Grant on February 17, 2026.
Who are the main investors in Linnaeus Therapeutics?
Key investors in Linnaeus Therapeutics include National Cancer Institute, Kairos Ventures, Kairos Ventures.
Will Linnaeus Therapeutics IPO soon?
No public IPO plans have been announced for Linnaeus Therapeutics.
How can I track Linnaeus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Linnaeus Therapeutics's shares on secondary markets.